Hiporfin-Mediated Photodynamic Therapy in Preclinical Treatment of Osteosarcoma (pages 533–544)
Mengxiong Sun, Chenghao Zhou, Hui Zeng, Nahum Puebla-Osorio, Elisabetta Damiani, Jian Chen, Hongsheng Wang, Guodong Li, Fei Yin, Liancheng Shan, Dongqing Zuo, Yuxin Liao, Zhuoying Wang, Longpo Zheng, Yingqi Hua and Zhengdong Cai
Article first published online: 16 FEB 2015 | DOI: 10.1111/php.12424
Hiporfin is one kind of photosensitizer that has been approved by Chinese SFDA. In this study, hiporfin was used to see its photodynamic activity in osteosarcoma. After illumination by 630 nm laser, hiporfin killed osteosarcoma cells by increased ROS level and through apoptosis and necroptosis pathways. In vivo study also showed potent tumor eradication. All these provided evidences for the clinical trial of hiporfin on osteosarcoma.